Dihydroergotamine Completed Phase 3 Trials for Migraine Disorders Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00623636Phase 3 Study of MAP0004 in Adult Migraineurs